BRIEF published on 07/29/2025 at 07:05, 10 months 28 days ago Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech SIX Swiss Exchange Mergers & Acquisitions Neurological Diseases AI Health Tech MindMaze
BRIEF published on 07/29/2025 at 07:05, 10 months 28 days ago Relief Therapeutics et NeuroX fusionnent, développant ainsi leur technologie de santé basée sur l'IA SIX Swiss Exchange Fusions Et Acquisitions Maladies Neurologiques MindMaze Technologie De La Santé Basée Sur L'IA
PRESS RELEASE published on 07/29/2025 at 07:00, 10 months 28 days ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 1 year ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
BRIEF published on 06/20/2025 at 07:05, 1 year ago Relief Therapeutics fait face à un revers de la FDA concernant la désignation QIDP du RLF-TD011 RLF-TD011 Médicament Orphelin Réponse De La FDA Epidermolyse Bulleuse Désignation QIDP
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 1 year ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
BRIEF published on 06/12/2025 at 11:05, 1 year ago Relief Therapeutics annonce les résultats de son assemblée générale annuelle États Financiers Réunion Annuelle Approbation Des Actionnaires Élections Du Conseil D'administration Approbation De L'indemnisation
PRESS RELEASE published on 06/12/2025 at 11:00, 1 year ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
BRIEF published on 05/22/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Secures FDA Rare Pediatric Disease Designation for RLF-TD011 FDA Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Rare Pediatric Disease
Published on 06/26/2026 at 01:40, 10 hours 51 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 13 hours 1 minute ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 14 hours 1 minute ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 14 hours 59 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 21 hours 1 minute ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 12:18, 13 minutes ago EQS-Adhoc: EPH Group AG: EPH Group AG Extends Subscription Period for New EPH Shares Until 31 July 2026
Published on 06/26/2026 at 11:14, 1 hour 16 minutes ago EQS-Adhoc: Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the outlook for the financial year 2026
Published on 06/26/2026 at 11:05, 1 hour 26 minutes ago Join the Beautiful Game: Discover Immersive Fan Experiences with Hisense at FIFA World Cup 2026™
Published on 06/26/2026 at 10:59, 1 hour 32 minutes ago HELIOS SOLAR AG starts subscription period for Initial Public Offering – shares offered at EUR 4.00
Published on 06/26/2026 at 07:00, 5 hours 31 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 5 hours 31 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 17 hours 46 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 18 hours 1 minute ago Avis financier semestriel SIEHM au 30 avril 2026
